News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Advectus Life Sciences Inc. - Pre-clinical brain cancer testing underway


Posted on: 07/01/2002

Monday July 01, 9:00 am Eastern Time

Press Release
SOURCE: Advectus Life Sciences Inc.

Advectus Life Sciences Inc. - Pre-clinical brain cancer testing underway

AVX: TSX VENTURE WKN. 693000 BERLIN AVXSF. NASD
VANCOUVER, July 1 /CNW/ - Advectus Life Sciences Inc. announced today that pre-clinical testing of its patented nanoparticle based technology (Nanocure(TM)) has commenced at the University of North Carolina Brain Tumor Center. This series of studies will test the Nanocure(TM) formulation P80DOX- NP on rodent brain metastases arising from lung carcinoma (2), breast carcinoma, melanoma, renal cell carcinoma, and colon carcinoma.

P80DOX-NP is a novel method for the delivery of doxorubicin across the blood-brain barrier. The above study design will be a randomized, placebo- controlled study measuring survival as a surrogate for intracranial tumor progression/regression. Successful demonstration of an antitumor effect will serve as a basis for a clinical trial using P80DOX-NP to treat the large group of patients with brain metastases. The study is designed to lead into Phase I Clinical Trials.

The mission of the University of North Carolina Brain Tumor Center at Chapel Hill is to lead the fight against brain tumors by providing patients with access to the best and most current therapies. UNC - CH collaborates closely with other brain tumor centers to find new treatments and make those new treatments available to all patients as soon as possible. UNC-CH welcomes the opportunity to work with colleagues at other institutions in order to advance the battle against brain tumors.

Advectus Life Sciences Inc. (AVX:TSX VENTURE) is a development stage company focused on the development and commercialization of a patented process using nanotechnology for the delivery of approved cancer fighting drugs across the blood-brain barrier for the treatment of brain tumors. For more information about Advectus Life Sciences, visit http://www.advectuslifesciences.com/

ON BEHALF OF THE BOARD OF ADVECTUS LIFE SCIENCES INC.

James H. Disher, President and Director

For further information

James H. Disher, Telephone: (604) 926-6098, Facsimile: (604) 926-4398, E-mail: info@advectuslifesciences.com, Website: http://www.advectuslifesciences.com
Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740